877133-58-9

Usage

Uses

Used in Pharmaceutical Industry:
3-PYRIDINOL, 6-CHLORO-4-IODOis used as a key intermediate for the synthesis of pharmaceuticals, contributing to the development of compounds with significant biological activities. Its unique structural features, including the presence of chlorine and iodine atoms, enable the creation of a diverse range of therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 3-PYRIDINOL, 6-CHLORO-4-IODOis utilized as a crucial component in the synthesis of agrochemicals, playing a vital role in the production of effective and targeted pest control solutions.
Used in Organic Synthesis:
3-PYRIDINOL, 6-CHLORO-4-IODOis employed as a building block in organic synthesis, allowing for the preparation of various functionalized molecules with specific applications across different industries. Its versatility and reactivity make it an essential component in the synthesis of complex organic compounds.

InChI:InChI=1/C5H3ClINO/c6-5-1-3(7)4(9)2-8-5/h1-2,9H

Upstream product

• 877133-56-7 2-chloro-5-(methoxymethoxy)pyridine 
• 41288-96-4 6-chloropyridine-3-ol 
• 877133-57-8 2-chloro-4-iodo-5-(methoxymethoxy)pyridine 

Downstream Products

• 1441754-60-4 5-(2-chloro-5-methoxy-pyridin-4-yl)-4-(4-chloro-2-methyl-phenyl)-3-isopropyl-2-(2-methoxy-phenyl)-4,5-dihydro-2H-pyrrolo[3,4-c]pyrazol-6-one 
• 1211516-07-2 2-chloro-4-iodo-5-methoxy-pyridine 
• 1451163-47-5 4-[5-(2-fluoro-4-methanesulfonyl-phenyl)-furo[2,3-c]pyridin-2-yl]-piperidine-1-carboxylic acid 1-methyl-cyclopropyl ester 
• 1451163-46-4 4-[5-(2-fluoro-4-methanesulfonyl-phenyl)-furo[2,3-c]pyridin-2-yl]-piperidine-1-carboxylic acid isopropyl ester 
• 1451163-45-3 5-(2-fluoro-4-methanesulfonyl-phenyl)-2-[1-(2-fluoro-2-methyl-propyl)-piperidin-4-yl]-furo[2,3-c]pyridine 
• 1451163-44-2 5-(2-fluoro-4-methanesulfonyl-phenyl)-2-[1-(1-trifluoromethyl-cyclopropylmethyl)-piperidin-4-yl]-furo[2,3-c]pyridine 
• 1451163-43-1 2-[1-(5-ethyl-pyrimidin-2-yl)-piperidin-4-yl]-5-(2-fluoro-4-methanesulfonyl-phenyl)-furo[2,3-c]pyridine 
• 1451163-39-5 4-[5-(4-methanesulfonylmethyl-phenyl)-furo[2,3-c]pyridin-2-yl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1451163-36-2 4-[5-(4-benzyloxycarbonyl-phenyl)-furo[2,3-c]pyridin-2-yl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1451163-33-9 4-[5-(4-ethylcarbamoyl-phenyl)-furo[2,3-c]pyridin-2-yl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1451163-32-8 4-[5-(4-cyano-3-fluoro-phenyl)-furo[2,3-c]pyridin-2-yl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1382136-84-6 4-[5-(2-fluoro-4-methanesulfonyl-phenyl)-furo[2,3-c]pyridin-2-yl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1451163-59-9 1-{4-[5-(2-fluoro-4-methanesulfonyl-phenyl)-furo[2,3-c]pyridin-2-yl]-piperidin-1-yl}-2-methyl-propan-2-ol 
• 1451163-58-8 5-(2-fluoro-4-methanesulfonyl-phenyl)-2-piperidin-4-yl-furo[2,3-c]pyridine 

Relevant academic research and scientific papers

Heterocyclic compound as FGFR inhibitor, synthesis method and applications thereof

The present invention discloses a heterocyclic compound as an FGFR inhibitor, and a synthesis method thereof, and applications of the heterocyclic compound in preparation of drugs for treating cancers. According to the present invention, the heterocyclic compound as the FGFR inhibitor or the pharmaceutically acceptable salt thereof has high FGFR inhibitory action, and the pharmaceutical composition prepared from the heterocyclic compound has good anticancer effect and wide application range.

1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS

The invention is concerned with the compounds of formula I and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.

COMPOUNDS AND METHODS OF USE

This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGFβ) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.

Pyrazolopyrrolidine compounds

The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS

The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.

IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT' OF CANCER

The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. wherein: R1 hydrogen, hydroxy, halo, methyl, C1-C2 alkoxy, amino, or rnethylamino; R2 is hydrogen, halo, or cyano; R3 is hydrogen or halo;, R4 is hydrogen, halo, or methyl; provided that at least two of R1, R2, R3, and R4 are hydrogen; R5 is hydrogen, halo, or methyl; or a pharmaceutically acceptable salt thereof.